PharmaCyte Biotech Inc (PMCB)

[urup]

"In our view, PharmaCyte Biotech sits in an enviable position, with multiple shots on goal as a potential universal therapy for the treatment of multiple forms of cancer and diabetes. The Company's flagship technology, Cell-in-a-Box®, has recently been granted Orphan Drug Status by the FDA for the treatment of advanced, inoperable pancreatic cancer when used in combination with the chemotherapy drug ifosfamide at one-third the dose normally given. This designation serves as a major boost to the Company's development efforts, its standing as a key player in the pancreatic cancer treatment arena and validates the Cell-in-a-Box® technology."

"Moreover, PharmaCyte Biotech has achieved enviable developmental progress over the past year and the launch of a series of clinical trials in 2015 should raise the Company's profile. These milestones include mid-stage and preclinical studies for the treatment of pancreatic cancer and its serious and debilitating symptoms, and for diabetes. Based on our pancreatic treatment peer group analysis alone, PharmaCyte Biotech's progress and industry status appear grossly overlooked. Considering the potential technology portability into the treatment of diabetes, a disease affecting millions with no cure, and other forms of cancer, the future potential reach of the technology may be greater than that of typical mid-stage biotechs."